Top

Published in:

01-10-2016 | Lung Cancer (HA Wakelee, Section Editor)

Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?

Authors: Lucio Buffoni, MD, Tiziana Vavalà, MD, Silvia Novello, MD, PhD

Published in: Current Treatment Options in Oncology | Issue 10/2016

Opinion statement

Twenty years ago, an individual patient data meta-analysis of eight cisplatin-based adjuvant chemotherapy (AC) studies in completely resected early stage non-small cell lung cancer (NSCLC) demonstrated a 13 % reduction of the risk of death favoring chemotherapy that was of borderline statistical significance (p = 0.08). This marginal benefit boosted a new generation of randomized trials to evaluate the role of modern platinum-based regimens in resectable stages of NSCLC and, although individual studies generated conflicting results, overall they contributed to confirm the role of AC which is now recommended for completely resected stage II and III NSCLC, mostly 4 cycles, while subset analyses suggested a benefit in patients with large IB tumors. Cisplatin-based therapy was the core regimen of those adjuvant clinical trials and even if a substitution with other platinum-derived was also suggested, mainly based on extrapolated data from studies in advanced disease, cisplatin was confirmed to be slightly superior to carboplatin and is still the drug of choice in the adjuvant setting. Currently, any attempt to improve efficacy of cisplatin-based chemotherapy through antiangiogenic drugs association or pharmacogenomics approaches have failed, while results of additional studies are eagerly awaited. In the context of promising targeted therapies, even if several randomized trials in the advanced setting evaluated tyrosine kinase inhibitors (TKis) versus platinum-based chemotherapy and showed impressive results, clinical experience with TKIs in the adjuvant setting is still limited and most of the trials have not required patients to be molecularly tested for the drug-specific molecular predictive factor. At the present time, the role of targeted agents as adjuvant approaches remains largely not investigated. Finally, with the negative experience of the use of vaccines in this setting, the integration of immunotherapy (mainly immunocheckpoint inhibitors) in platinum-based schedules has just started to be evaluated, representing a potential future clinical option, but still far from clinical practice.

Le Chevalier T. Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going? Ann Oncol. 2010;21(Supplement 7):vii196–8. doi:10.1093/annonc/mdq376.CrossRefPubMed

Vansteenkiste J, Crinò L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, et al. 2nd ESMO consensus conference on lung cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol. 2014;00:1–13. doi:10.1093/annonc/mdu089.

No Authors listed. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-small cell Lung Cancer Collaborative Group. BMJ. 1995;311:889–909. doi:10.1136/bmj.311.7010.899

Scagliotti GV, Fossati R, Torri V, Crinò L, Giaccone G, Silvano G, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst. 2003;95(19):1453–61. doi:10.1093/jnci/djg059.CrossRefPubMed

Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, Parmar MK, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the big lung trial. Eur J Cardiothorac Surg. 2004;26(1):173–82. doi:10.1016/j.ejcts.2004.03.041.CrossRefPubMed

Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small cell lung cancer. Eastern cooperative oncology group. N Engl J Med. 2000;343(17):1217–22. doi:10.1056/NEJM200010263431703.CrossRefPubMed

Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010;28(1):35–42. doi:10.1200/JCO.2009.23.2272.CrossRefPubMed

Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–97. doi:10.1056/NEJMoa043623.CrossRefPubMed

Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]: a randomised controlled trial. Lancet Oncol. 2006;7:719–27. doi:10.1016/S1470-2045(06)70804-X.CrossRefPubMed

10.

Strauss GM, Herndon 2nd JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non small-cell lung cancer: CALGB 9633 with the cancer and leukemia group B, radiation therapy oncology group, and north central cancer treatment group study groups. J Clin Oncol. 2008;26:5043–51. doi:10.1200/JCO.2008.16.4855.CrossRefPubMedPubMedCentral

11.

Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26(21):3552–9. doi:10.1200/JCO.2007.13.9030.CrossRefPubMed

12.

NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375(9722):1267–77. doi:10.1016/S0140-6736(10)60059-1.CrossRefPubMedCentral

13.

Zhong C, Liu H, Jiang L, Zhang W, Yao F. Chemotherapy plus best supportive care versus best supportive care in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trials. PLoS One. 2013;8(3):e58466. doi:10.1371/journal.pone.0058466.CrossRefPubMedPubMedCentral

14•.

Massuti B, Sanchez JM, Hernando-Trancho F, Karachaliou N, Rosell R. Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer? Transl Lung Cancer Res. 2013;2(3):208–21. doi:10.3978/j.issn.2218-6751.2013.03.06 .This article describes the most promising clinicopathological and molecular biomarkers with predictive and prognostic significance in lung cancer which could influence adjuvant and neoadjuvant chemotherapy decisions for operable NSCLC in routine clinical practicePubMedPubMedCentral

15.

Oloaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:981–91. doi:10.1056/NEJMoa060570.

16.

Wislez M, Barlesi F, Besse B, Mazières J, Merle P, Cadranel J, et al. Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE. J Clin Oncol. 2014;32(12):1256–61. doi:10.1200/JCO.2013.53.1525.CrossRefPubMed

17.

Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013;368(12):1101–10. doi:10.1056/NEJMoa1214271.CrossRefPubMedPubMedCentral

18.

Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist. 2009;14(3):253–63. doi:10.1634/theoncologist.2008-0232.CrossRefPubMed

19.

Nakagawa T, Otake Y, Yanagihara K, Miyahara R, Ishikawa S, Fukushima M, et al. Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). Lung Cancer. 2004;43(2):145–9. doi:10.1016/j.lungcan.2003.09.004.CrossRefPubMed

20.

Shintani Y, Ohta M, Hirabayashi H, Tanaka H, Iuchi K, Nakagawa K, et al. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-timereverse transcription polymerase chain reaction. Int J Cancer. 2003;104(6):790–5. doi:10.1002/ijc.11014.CrossRefPubMed

21.

Zheng Z, Li X, Schell MJ, Chen T, Boulware D, Robinson L, et al. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer. 2008;112(12):2765–73. doi:10.1002/cncr.23491.CrossRefPubMed

22.

Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2004;10:1318–25. doi:10.1158/1078-0432.CCR-03-0156.CrossRefPubMed

23.

Novello S, Grohe C, Geissler M, Serke MH, Colantonio I, Meyer A, et al. Preliminary results of the international tailored chemotherapy adjuvant trial: the ITACA trial. J Thorac Oncol. 2015;10(9):Supplement 2:s179.

24.

Massuti B, Rodriguez-Paniagua JM, Cobo Dols M, Arraba R, Ballesteros I, Pun YW, et al. Results phase III trial customized adjuvant CT after resection of NSCLC with lymph node metastases SCAT: a Spanish lung cancer group trial. J Thorac Oncol. 2015;10(9):Supplement 2:s180.

25.

Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, et al. Randomized phase III trial of adjuvant chemotherapy with or without bevacizumab in resected non-small cell lung cancer (NSCLC): results of E1505. JTO. 2015;10(9):Supplement 2:s66.

26.

Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL et al. E1505: adjuvant chemotherapy +/− bevacizumab for early stage NSCLC—outcomes based on chemotherapy subsets. J Clin Oncol. 2016;34(15):Suppl: 8507.

27.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell-lung cancer (EURTAC): a multicentre, open-label, randomisedphase3 trial. Lancet Oncol. 2012;13(3):239–46. doi:10.1016/S1470-2045(11)70393-X.CrossRefPubMed

28.

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu D, Saijo N, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57. doi:10.1056/NEJMoa0810699.CrossRefPubMed

29.

Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-lung 6): an open-label, randomisedphase3 trial. Lancet Oncol. 2014;15(2):213–22. doi:10.1016/S1470-2045(13)70604-1.CrossRefPubMed

30.

Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32. doi:10.1056/NEJMoa050753.CrossRefPubMed

31.

Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-lung 8): an open-label randomized controlled phase 3 trial. Lancet Oncol. 2015;16(8):897–907. doi:10.1016/S1470-2045(15)00006-6.CrossRefPubMed

32.

Shi Y, Wang L, Han B, Li W, Yu P, Liu Y, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance in advanced NSCLC patients with EGFR mutation. J Thor Oncol. 2015;10(9):suppl 2:S205.

33.

Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–77. doi:10.1056/NEJMoa1408440.CrossRefPubMed

34.

Tsao MS, Sakurada A, Ding K, Aviel-Ronen S, Ludkovski O, Liu N, et al. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer. J Thor Oncol. 2011;6:139–47. doi:10.1097/JTO.0b013e3181fd83a4.CrossRef

35.

Bai H, Wang Z, Chen K, Zhao J, Lee JJ, Wang S, et al. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol. 2012;30:3077–83. doi:10.1200/JCO.2011.39.3744.CrossRefPubMed

36.

Janjigian YY, Park BJ, Zakowski MF, Ladanyi M, Pao W, D’Angelo SP, et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinoma as that harbor EGFR mutations. J Thorac Oncol. 2011;6:569–75. doi:10.1097/JTO.0b013e318202bffe.CrossRefPubMedPubMedCentral

37.

Tsuboi M, Kato H, Nagai K, Tsuchiya R, Wada H, Tada H, et al. Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer. Anti-Cancer Drugs. 2005;16:1123–8.CrossRefPubMed

38.

Goss GD. O′ Callaghan C, Lorimer I, Tsao MS, masters GA, Jett J et al. gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol. 2013;31(27):3320–6. doi:10.1200/JCO.2013.51.1816.CrossRefPubMedPubMedCentral

39.

Kelly K, Chansky K, Gaspar LE Albain KS, Jett J, Ung YC, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008;26:2450–6. doi:10.1200/JCO.2007.14.4824.CrossRefPubMed

40.

Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer). Lancet. 2005;366:1527–37. doi:10.1016/S0140-6736(05)67625-8.CrossRefPubMed

41.

Kelly K, Altorki NK, Eberhardt WE, O’Brien ME, Spigel DR, Crinò L, et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind. Phase III Trial J Clin Oncol. 2015;33(34):4007–14. doi:10.1200/JCO.2015.61.8918.PubMed

42.

Novello S. Epidermal growth factor receptor tyrosine kinase inhibitors as adjuvant therapy in completely resected non-small-cell lung cancer. J Clin Oncol. 2015;33(34):3985–6. doi:10.1200/JCO.2015.63.7587.CrossRefPubMed

43.

Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, et al. ALCHEMIST trials: a golden opportunity to transform outcomes in early-stage non–small cell lung cancer. Clin Cancer Res. 2015;21:5439–44. doi:10.1158/1078-0432.CCR-15-0354.CrossRefPubMed

44.

Remon J, Soria JC. Personalized medicine. J Thor Oncol. 2015;10(9):suppl 2:s69.

45.

Niu FY, Zhong WZ, Zhou Q, Wu YL. Clinical trials for lung cancer in China. Transl Lung Cancer Res. 2014;3(5):311–6. doi:10.3978/j.issn.2218-6751.2014.10.04.PubMedPubMedCentral

46.

Lourdes LS, Jalal SI, Hanna N. Adjuvant epidermal growth factor receptor inhibitors in non-small cell lung cancer. Oncologist. 2015;20:975–8. doi:10.1634/theoncologist.2015-0182.CrossRefPubMedPubMedCentral

47••.

Hirsch FR, Bunn Jr PA. Adjuvant TKIs in NSCLC: what can we learn from RADIANT? Nature Reviews. 2015;12:689–90. doi:10.1038/nrclinonc.2015.202.In this article Authors discuss about RADIANT trial results, comparing these data to others present in literature and underlying the most relevant open questions about EGFR-TKI treatment in the adjuvant settingPubMed

48.

Vansteenkiste JF, Cho B, Vanakesa T, De Pas T, Zielinski M, Kim MS, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2016. doi:10.1016/S1470-2045(16)00099-1.

49.

Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol. 2013;31(19):2388–95. doi:10.1200/JCO.2012.44.3762.CrossRefPubMed

50.

Lena H, Rizvi NA, Wolf J, Cappuzzo F, Zalcman G, Baas P, et al. 137O: nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profiling analyses. J Thorac Oncol. 2016;11(4 Suppl):S115–6. doi:10.1016/S1556-0864(16)30247-7.CrossRefPubMed

51.

Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50. doi:10.1016/S0140-6736(15)01281-7.CrossRefPubMed

52.

Johnson DB, Rioth MJ, Horn L. Immune checkpoint inhibitors in NSCLC. Curr Treat Options in Oncol. 2014;15(4):658–69. doi:10.1007/s11864-014-0305-5.CrossRef

53.

A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS). https://clinicaltrials.gov/ct2/show/NCT02504372. Accessed 19 May 2016.

54.

Double blind placebo controlled study of adjuvant MEDI4736 in completely resected NSCLC. https://clinicaltrials.gov/ct2/show/NCT02273375. Accessed 19 May 2016.

55.

Study to assess safety and efficacy of atezolizumab (MPDL3280A) compared to best supportive care following chemotherapy in patients with lung cancer. https://clinicaltrials.gov/ct2/show/NCT02486718. Accessed 19 May 2016.

Title: Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?
Authors: Lucio Buffoni, MD
Tiziana Vavalà, MD
Silvia Novello, MD, PhD
Publication date: 01-10-2016
Publisher: Springer US
Published in: Current Treatment Options in Oncology / Issue 10/2016
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-016-0429-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Opinion statement

Please log in to get access to this content

Other articles of this Issue 10/2016

The Benefit of a Multidisciplinary Approach to the Patient Treated with (Chemo) Radiation for Head and Neck Cancer

Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma

Sequencing of New and Old Therapies for Metastatic Melanoma

The Role of Molecular Diagnostics in the Management of Patients with Gliomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer